Rapport Therapeutics, Inc.
RAPP
$38.08
$0.842.26%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 20.00M | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 20.00M | -- | -- | -- | -- |
| Cost of Revenue | 32.72M | 19.57M | 19.57M | 19.57M | 19.57M |
| Gross Profit | -12.72M | -19.57M | -19.57M | -19.57M | -19.57M |
| SG&A Expenses | 34.27M | 30.31M | 28.38M | 26.77M | 25.07M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 142.21M | 125.10M | 110.11M | 101.77M | 93.07M |
| Operating Income | -122.21M | -125.10M | -110.11M | -101.77M | -93.07M |
| Income Before Tax | -107.28M | -111.48M | -97.70M | -88.31M | -79.70M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -107.28 | -111.48 | -97.70 | -88.31 | -79.70 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -107.28M | -111.48M | -97.70M | -88.31M | -79.70M |
| EBIT | -122.21M | -125.10M | -110.11M | -101.77M | -93.07M |
| EBITDA | -121.21M | -124.08M | -109.10M | -100.79M | -92.14M |
| EPS Basic | -2.60 | -2.87 | -2.72 | -2.51 | -3.45 |
| Normalized Basic EPS | -1.63 | -1.79 | -1.70 | -1.57 | -2.16 |
| EPS Diluted | -2.60 | -2.87 | -2.72 | -2.51 | -3.45 |
| Normalized Diluted EPS | -1.63 | -1.79 | -1.70 | -1.57 | -2.16 |
| Average Basic Shares Outstanding | 167.59M | 155.62M | 143.71M | 140.64M | 115.86M |
| Average Diluted Shares Outstanding | 167.59M | 155.62M | 143.71M | 140.64M | 115.86M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |